Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Merger or Acquisition (June 2022)
10 slides from Orion Oyj Class A's merger presentation, Jun 15, 2022
Slide 1: The acquisition of Inovet's animal health business V.M.D. NV
The acquisition of Inovet’s animal health business V.M.D. NV
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Transaction details
Transaction details Purchased V.M.D. NV & its subsidiaries Biové Laboratoires SAS, Biard SAS, V.M.D. companies Állatgyógyászati Kft and Inovet Indochine Co., Ltd. Seller Inovet BV – a family-owned Belgian private company Buyer Orion Corporation Transaction EUR 130 million debt free. Transaction will
Slide 4: V.M.D. NV in a nutshell
V.M.D. NV in a nutshell Net sales in 2021 EUR 61 million >220 products 7% ~180 employees Companion animals 93 % and small species Livestock animals >1,400 marketing authorisations Products sold in 120 countries 80% of products developed and Arendonk Arques Budapest Ho Chi manufactured in-house •HQ •
Slide 5: Orion Animal Health and VMD complement each other – no overlaps
Orion Animal Health and VMD complement each other – no overlaps Net sales in 2021 EUR 73 million EUR 61 million Personnel 72 181 Manufacturing sites 2 (Espoo, Turku) 1 (Arques) Manufacturing & Companion Food producing R&D focus animals animals Net sales split VMD Orion Animal Health Together 93% 25%
Slide 6: The way forward together
The way forward together Expanded geographical • Good basis for further geographical expansion presence with no overlaps • Attractive distribution and in-licensing partner Broad product portfolio • Cross selling opportunities covering both food producing • Access to new markets and customers animals
Slide 7: Q&A
Q&A
Slide 8: Orion at a glance (2021 figures)
Orion at a glance (2021 figures) Sales by business Sales by market area Net sales 1,041 MEUR 7% 13% Operating profit 243 MEUR 7% 30% 37% 9% Personnel 3,355 49% R&D investments 118 MEUR 34% 14% 6 production sites in Finland Proprietary Products Finland Specialty Products Scandinavia Other Europe Own
Slide 9: Orion Animal Health's net sales in 2021
Orion Animal Health’s net sales in 2021 EUR 73 million Sales split by product type Sales split by revenue type ~25% ~23% ~75% ~77% Companion animals Food producing animals + equine Own products In-licensed ©Orion Corporation 15 June 2021 9
Slide 10: Orion Animal Health – a mix of in-house developed proprietary products and in-licensed products
Orion Animal Health – a mix of in-house developed proprietary products and in-licensed products In-house developed proprietary products In-licensed products • Prescription medicines and nutraceutical • Prescription medicines and nutraceutical products products • Sold by Orion in own territories in E